BR0205983A - fármacos peptìdicos antiangiogênicos - Google Patents

fármacos peptìdicos antiangiogênicos

Info

Publication number
BR0205983A
BR0205983A BRPI0205983-5A BR0205983A BR0205983A BR 0205983 A BR0205983 A BR 0205983A BR 0205983 A BR0205983 A BR 0205983A BR 0205983 A BR0205983 A BR 0205983A
Authority
BR
Brazil
Prior art keywords
peptide drugs
antiangiogenic peptide
antiangiogenic
angiogenesis
inhibiting
Prior art date
Application number
BRPI0205983-5A
Other languages
English (en)
Inventor
Jack Henkin
Fortuna Henkin
Michael F Bradley
Kalvin M Douglas
Andrew J Schneider
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR0205983A publication Critical patent/BR0205983A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FáRMACOS PEPTìDICOS ANTIANGIOGêNICOS". A presente invenção descreve peptídeos que são úteis para inibir angiogênse. Descreve-se também composições inibidoras de angiogênese e métodos para inibir angiogênese em um mamífero.
BRPI0205983-5A 2001-04-11 2002-04-10 fármacos peptìdicos antiangiogênicos BR0205983A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,733 US20020183242A1 (en) 2001-04-11 2001-04-11 Peptide antiangiogenic drugs
PCT/US2002/011027 WO2002083065A2 (en) 2001-04-11 2002-04-10 Peptide antiangiogenic drugs

Publications (1)

Publication Number Publication Date
BR0205983A true BR0205983A (pt) 2006-05-23

Family

ID=25262479

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0205983-5A BR0205983A (pt) 2001-04-11 2002-04-10 fármacos peptìdicos antiangiogênicos

Country Status (10)

Country Link
US (1) US20020183242A1 (pt)
EP (1) EP1429796A4 (pt)
JP (1) JP2005510452A (pt)
AU (1) AU2002303278A1 (pt)
BR (1) BR0205983A (pt)
CA (1) CA2443733A1 (pt)
MX (1) MXPA03009278A (pt)
PE (1) PE20021078A1 (pt)
UY (1) UY27254A1 (pt)
WO (1) WO2002083065A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
MX345535B (es) 2011-05-06 2017-02-03 Zafgen Inc Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
AU2013259620B2 (en) 2012-05-09 2017-05-18 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2014071363A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200937A (en) * 1988-09-29 1993-04-06 Canon Kabushiki Kaisha Apparatus for and method of recording and/or reproducing information by means of two actuators
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
ATE280781T1 (de) * 1997-03-17 2004-11-15 Abbott Lab Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
DE69938782D1 (de) * 1998-05-22 2008-07-03 Abbott Lab Peptide als antiangiogene arzneimittel
DK1232183T3 (da) * 1999-11-22 2006-05-29 Abbott Lab Peptider, som har antiangiogen aktivitet
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica

Also Published As

Publication number Publication date
WO2002083065A2 (en) 2002-10-24
WO2002083065A3 (en) 2004-01-08
CA2443733A1 (en) 2002-10-24
JP2005510452A (ja) 2005-04-21
PE20021078A1 (es) 2002-12-18
US20020183242A1 (en) 2002-12-05
UY27254A1 (es) 2002-11-29
EP1429796A2 (en) 2004-06-23
EP1429796A4 (en) 2005-01-12
MXPA03009278A (es) 2004-03-10
AU2002303278A1 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
BR0205983A (pt) fármacos peptìdicos antiangiogênicos
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
ATE317854T1 (de) Hepatitis c inhibitor peptide
ATE260644T1 (de) Peptid/lipid-komplexbildung durch co- lyophilisation
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
ATE396204T1 (de) Peptide als antiangiogene arzneimittel
ATE368053T1 (de) Antimikrobielle peptide
ATE464060T1 (de) Peroral-verabreichte peptide zur besserung von atherosklerose
DE69935579D1 (de) Am kopf montiertes projektionsanzeigsystem
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
NO20073914L (no) Biologisk aktive peptider
MEP38608A (en) Gonadotrophins for folliculogenesis
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
DE60232905D1 (de) Informationsanzeigeeinheit
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
EP2292273A3 (en) Remodeling and glycoconjugation of peptides
DE69938130D1 (de) Neue peptide
EP1385556A4 (en) PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS
EP1489093A4 (en) PEPTIDES, MEDICAL COMPOSITIONS CONTAINING PEPTIDES, AND MEDICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
DK0977871T3 (da) Neurotrypsin
IL150458A0 (en) Novel haptotactic peptides
IL158411A0 (en) Peptides that inhibit viral infections and compositions containing the same
GB2380998B (en) D-amino acid peptide for security tagging
GB0108752D0 (en) Peptide epitopes and uses thereof
ECSP972320A (es) METODOS Y COMPOSICIONES PARA INHIBIR LA LIBERACION DE PEPTIDO ß- AMILOIDE Y/O SU SINTESIS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.